Therapeutic Response to Rituximab in IgG4-Related Hypophysitis Evidenced on 18F-FDG PET and MRI
| Autor: | Boramy Hay, Aurélie Bourdon, Fayçal Ben Bouallègue, Denis Mariano-Goulart, Fabien Vauchot |
|---|---|
| Přispěvatelé: | Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiologie des Adaptations Nutritionnelles [UMR_A1280] (PhAN), Institut National de la Recherche Agronomique (INRA)-Université de Nantes (UN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service de médecine nucléaire [Montpellier] |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Hypophysitis [SDV]Life Sciences [q-bio] IgG4-Related Hypophysitis 030218 nuclear medicine & medical imaging 18f fdg pet Lesion 03 medical and health sciences 0302 clinical medicine rituximab Fluorodeoxyglucose F18 medicine Humans Autoimmune Hypophysitis Radiology Nuclear Medicine and imaging IgG4-related disease Aged medicine.diagnostic_test business.industry therapeutic response Magnetic resonance imaging General Medicine medicine.disease Magnetic Resonance Imaging 3. Good health hypophysitis Positron emission tomography Positron-Emission Tomography 030220 oncology & carcinogenesis Rituximab Radiology Radiopharmaceuticals medicine.symptom business medicine.drug 18F-FDG PET |
| Zdroj: | Clinical Nuclear Medicine Clinical Nuclear Medicine, Lippincott, Williams & Wilkins, 2019, 44 (5), pp.e362-e363. ⟨10.1097/RLU.0000000000002514⟩ Clinical Nuclear Medicine, Lippincott, Williams & Wilkins, 2019, ⟨10.1097/RLU.0000000000002514⟩ |
| ISSN: | 0363-9762 |
| DOI: | 10.1097/RLU.0000000000002514⟩ |
| Popis: | International audience; Baseline F-FDG PET and MRI were performed in a patient with IgG4-related hypophysitis, showing a 15-mm hypervascular hypermetabolic lesion with sellar and suprasellar extension. Lack of response after 10 months of first-line corticosteroid therapy was demonstrated on both F-FDG PET and MRI. Three months later, after 2 injections of 1 g of rituximab associated with continued corticosteroid therapy, MRI showed substantial shrinkage of the pituitary lesion with minimal residual Gd enhancement, whereas F-FDG PET evidenced complete metabolic response. As such, joint F-FDG PET and MRI assessment during therapy may have a potential interest for treatment response evaluation in pituitary IgG4-related disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|